The strong presence of pharmaceutical manufacturers, increasing investments in reproductive medicine research, and expanding availability of fertility treatment services are supporting market development across North America. Growing demand for hormonal therapies and continuous advancements in assisted reproductive technologies are further encouraging the adoption of hCG products.

Market Overview

The global Human Chorionic Gonadotropin (hCG) Market was valued at US$ 1.21 billion in 2024 and is expected to reach US$ 1.85 billion by 2031. The market is anticipated to register a CAGR of 6.2% during 2025–2031.

Human chorionic gonadotropin is a hormone widely used in reproductive medicine and fertility treatment applications. It supports ovulation induction in women and is used in selected treatments involving male hypogonadism and oligospermia. Increasing awareness of reproductive health, rising infertility rates, and expanding access to fertility clinics are contributing to market development.

Download Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00004577

Key Market Drivers and Trends

Increasing Demand for Fertility Treatments: The growing prevalence of infertility and increasing demand for assisted reproductive technologies are major factors supporting the hCG market. Fertility clinics are increasingly using hormone-based treatments as part of ovulation induction and assisted reproductive procedures. Growing awareness of fertility preservation and reproductive health is also contributing to market demand.

Rising Awareness of Reproductive Health: Increasing awareness of reproductive health conditions among men and women is encouraging early diagnosis and treatment. Improved access to fertility consultations, hormonal assessments, and specialized reproductive healthcare services is supporting the adoption of hCG-based treatments.

Growing Adoption of Recombinant Technology: Advancements in recombinant technology are creating opportunities for the development of human chorionic gonadotropin products. Recombinant production approaches support controlled manufacturing processes and product consistency, encouraging pharmaceutical companies to invest in innovative hormone-based therapies.

Increasing Prevalence of Male Hypogonadism: Growing awareness and diagnosis of male hypogonadism are supporting demand for hormonal treatment options. hCG is used in selected clinical settings to stimulate testosterone production and support reproductive functions, contributing to its application in male reproductive healthcare.

Advancements in Drug Delivery Systems: Pharmaceutical manufacturers are exploring improved drug formulations and delivery systems to enhance treatment convenience and patient experience. Innovations in injectable formulations, product stability, and administration methods are supporting the development of advanced hCG products.

Growing Research and Development Activities: Increasing investments in reproductive medicine and hormonal research are creating new opportunities for market participants. Pharmaceutical companies and research institutions are exploring improved treatment approaches, manufacturing technologies, and potential applications of hCG.

Top Players in the Human Chorionic Gonadotropin (hCG) Market

• Merck & Co., Inc.

• Ferring B.V.

• Fresenius Kabi AG

• Cigna

• Sun Pharmaceutical Industries Ltd.

• Lee BioSolutions Inc.

• Sanzyme

• Scrippslabs

• Lupin AB

• Prospec-Tany Technogene Ltd.

Market Segmentation

The Human Chorionic Gonadotropin (hCG) Market is segmented based on technology, therapeutic area, and end user.

By Technology:

• Natural Source Extraction

• Recombinant Technology

By Therapeutic Area:

• Female Infertility Treatment

• Male Hypogonadism

• Oligospermic Treatment

• Others

By End User:

• Fertility Clinics

• Research Institutions

• Others

Regional Outlook

North America represents an important market for human chorionic gonadotropin due to advanced reproductive healthcare infrastructure, increasing awareness of infertility treatments, and the availability of specialized fertility clinics. The United States is a key market supported by growing investments in reproductive medicine, technological advancements, and increasing demand for fertility treatment services.

Europe is another significant regional market, supported by established healthcare systems, expanding fertility treatment services, and growing awareness of reproductive health conditions. Countries such as Germany, the United Kingdom, France, and Italy contribute to regional market development.

Asia Pacific is presenting growth opportunities due to increasing awareness of infertility, expanding healthcare infrastructure, and rising availability of assisted reproductive technologies. Countries such as China, India, Japan, and Australia are contributing to the development of reproductive healthcare services.

South and Central America are also witnessing opportunities through improvements in fertility treatment accessibility and expanding specialized healthcare services. Meanwhile, the Middle East and Africa market is supported by the gradual development of reproductive healthcare infrastructure and increasing awareness of hormonal treatments.

Future Outlook

The Human Chorionic Gonadotropin (hCG) Market is expected to experience steady growth through 2031 as demand for fertility treatments and specialized reproductive healthcare services continues to increase. Growing awareness of male and female infertility, expanding fertility clinic networks, and advancements in recombinant hormone production are expected to support market development.

Furthermore, technological advancements in pharmaceutical manufacturing, improved drug delivery systems, and increasing investments in reproductive medicine research are likely to create new opportunities for industry participants. Pharmaceutical companies focusing on product innovation, manufacturing quality, and expanding access to reproductive healthcare treatments are expected to strengthen their market positions during the forecast period.

Related Reports –

Infertility Testing Market Size, Share & Industry Growth by 2031

Male Hypogonadism Market Size, Share & Trends by 2034

About Us

The Insight Partners, we provide comprehensive analysis and insights into market trends that empower businesses to make informed decisions. Our reports are designed to equip stakeholders with the necessary information to navigate the complexities of various industries, including healthcare, technology, and finance. We are dedicated to delivering high-quality research that enables our clients to achieve their strategic objectives.

Contact Us:
Contact Person: Ankit Mathur
E-mail: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876

Also Available in : Korean German Japanese French Chinese Italian Spanish